NCT06626919 - A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

April 30, 2028

Conditions

Muscular DiseasesNeuromuscular ManifestationsAutoimmuneAutoimmune DiseasesAutoimmune Diseases of the Nervous SystemMyasthenia GravisMuscle Weakness

Interventions

BIOLOGICAL

anito-cel

Anitocabtagene autoleucel BCMA directed CAR T-cell therapy using a novel, synthetic binding domain, called a D-Domain

DRUG

Standard Lymphodepletion regimen

Standard lymphodepletion regimen subject receive 5 days prior to CAR T infusion

Trial Locations (9)

RECRUITING

Columbia University Irving Medical Center, New York

RECRUITING

Temple University Hospital, Philadelphia

RECRUITING

Ohio State University, Columbus

RECRUITING

Karmanos Cancer Institute, Detroit

RECRUITING

Houston Methodist Hospital, Houston

RECRUITING

UCLA Medical Center, Los Angeles

RECRUITING

University of California, Irvine, Orange

RECRUITING

Stanford Hospital, Palo Alto

RECRUITING

Oregon Health & Science University (OHSU), Portland